1. Academic Validation
  2. Rosmarinic acid treatment protects against lethal H1N1 virus-mediated inflammation and lung injury by promoting activation of the h-PGDS-PGD2-HO-1 signal axis

Rosmarinic acid treatment protects against lethal H1N1 virus-mediated inflammation and lung injury by promoting activation of the h-PGDS-PGD2-HO-1 signal axis

  • Chin Med. 2023 Oct 27;18(1):139. doi: 10.1186/s13020-023-00847-0.
Beixian Zhou # 1 Linxin Wang # 2 Sushan Yang # 1 Yueyun Liang 1 Yuehan Zhang 1 Xiping Pan 3 Jing Li 4
Affiliations

Affiliations

  • 1 The People's Hospital of Gaozhou, Gaozhou, 525200, China.
  • 2 Guangzhou Laboratory, Guangzhou, China.
  • 3 Guangzhou Laboratory, Guangzhou, China. xppan116@sina.com.
  • 4 State Key Laboratory of Respiratory Disease, National Clinical Research Center of Respiratory Disease, Guangzhou Institute of Respiratory Health, Institute of Chinese Integrative Medicine, Guangdong-Hongkong-Macao Joint Laboratory of Infectious Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, Guangdong, China. lijing82@gzhmu.edu.cn.
  • # Contributed equally.
Abstract

Background: Rosmarinic acid (RosA) is a natural phenolic compound that possesses a wide-range of pharmacological properties. However, the effects of RosA on influenza A virus-mediated acute lung injury remain unknown. In this study, we aimed to explore whether RosA could protect against H1N1 virus-mediated lung injury and elucidate the underlying mechanisms.

Methods: Mice were intragastrically administered with RosA for 2 days before intranasal inoculation of the H1N1 virus (5LD50) for the establishment of an acute lung injury model. At day 7 post-infection (p.i.), gross anatomic lung pathology, lung histopathologic, and lung index (lung weight/body weight) were examined. Luminex assay, multiple immunofluorescence and flow cytometry were performed to detect the levels of pro-inflammatory cytokines and Apoptosis, respectively. Western blotting and plasmid transfection with hematopoietic-type PGD2 synthase (h-PGDS) overexpression were conducted to elucidate the mechanisms.

Results: RosA effectively attenuated H1N1 virus-triggered deterioration of gross anatomical morphology, worsened lung histopathology, and elevated lung index. Excessive pro-inflammatory reactions, aberrant alveolar epithelial cell Apoptosis, and cytotoxic CD8+ T lung recruitment in the lung tissues induced by H1N1 virus Infection were observed to be reduced by RosA treatment. In vitro experiments demonstrated that RosA treatment dose-dependently suppressed the increased levels of pro-inflammatory mediators and Apoptosis through inhibition of nuclear factor kappa B (NF-κB) and p38 MAPK signaling pathways in H1N1 virus-infected A549 cells, which was accompanied by promoting activation of the h-PGDS-PGD2-HO-1 signal axis. Furthermore, we strikingly found that h-PGDS inhibition significantly abrogated the inhibitory effects of RosA on H1N1 virus-mediated activation of NF-κB and p38 MAPK signaling pathways, resulting in diminishing the suppressive effects on the increased levels of pro-inflammatory cytokines and chemokines as well as Apoptosis. Finally, suppressing h-PGDS prominently abolished the protective effects of RosA on H1N1 virus-mediated severe pneumonia and lung injury.

Conclusions: Taken together, our study demonstrates that RosA is a promising compound to alleviate H1N1 virus-induced severe lung injury through prompting the h-PGDS-PGD2-HO-1 signal axis.

Keywords

Apoptosis; H1N1 virus; HO-1; Inflammation; PGD2; Rosmarinic acid; h-PGDS.

Figures
Products